KEYNOTE-057: Phase II study of pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC) Meeting Abstract
| Authors: | Kamat, A. M.; Bellmunt, J.; Choueiri, T. K.; Nam, K.; De Santis, M.; Dreicer, R.; Hahn, N. M.; Perini, R.; Siefker-Radtke, A.; Sonpavde, G.; de Wit, R.; Witjes, J. A.; Keefe, S.; Bajorin, D. |
| Abstract Title: | KEYNOTE-057: Phase II study of pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC) |
| Meeting Title: | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 4 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2016 Nov 9-13 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2016-11-16 |
| Start Page: | 82 |
| Language: | English |
| DOI: | 10.1186/s40425-016-0172-7 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: P141 |
